Introduction
Coronavirus disease 2019 (COVID‐19), caused by a novel coronavirus called severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), is the most common global disease. The high-risk groups of this disease, which has been declared a pandemic by the world health organization (WHO) today, are still not fully determined. Immunosuppressed patients are regarded as a high‐risk cohort. In this view, previous experience with similar viruses, such as SARS-CoV and MERS-CoV, suggests that solid organ transplantation (SOT) recipients would be prone to have increased morbidity and mortality. Early published studies in liver transplantation (LT) and SOT recipients with COVİD-19 reported a rate of up to %20 [1], exceeding the rate of the general population [2].
Initial symptoms of patients with COVİD-19 are various, and the percentage of mild illness symptoms seen is about 80% [3]. Patients with SARS-Cov-2 may be completely asymptomatic or progress with severe disease. Comorbidities and advanced age are the most important risk factors among LT recipients and the general population [1]. It is estimated that COVID-19 will be more symptomatic and severe in LT recipients due to immunosuppression treatments. Our study aims to determine the frequency of asymptomatic or mild disease in the LT recipients.